The U.S. FDA completed its reinspection of Akorn Inc.'s facility in Decatur, Ill.

The reinspection is a follow-up to verify the implementation and effectiveness of Akorn's responses to the FDA's observations from a June inspection of the facility, which constituted six violations of the Food Drug and Cosmetic Act.